Ginkgo Bioworks Holdings (DNA) Liabilities and Shareholders Equity (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 20.13% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (down 20.84% YoY), and the FY2025 full-year result was $1.1 billion, down 18.71% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.0 billion, down from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.5 billion in Q4 2022 and bottomed at $1.0 billion in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.6 billion (2024), against an average of $1.7 billion.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity rose 22.61%; it then sank 34.56% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.5 billion in 2022, then plunged by 34.42% to $1.7 billion in 2023, then fell by 17.29% to $1.4 billion in 2024, then slipped by 18.71% to $1.1 billion in 2025, then retreated by 7.74% to $1.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison